This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research. NAC is a medication used to loosen thick mucus. NAC was initially licensed for use in 1968. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system, and it is available as a generic medication and is not very expensive. Inhaled NAC has been used as a mucus-dissolving therapy in respiratory conditions with excessive and/or thick mucus production.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Subject will receive N-acetyl cysteine first followed by Placebo
Subject will receive Placebo first followed by N-acetyl cysteine
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Changes in Pulmonary function - FVC
Measure changes in percent predicted FVC
Time frame: Baseline, week 10, and week 18
Changes in Pulmonary function - DLCO
Measure changes in percent predicted DLCO
Time frame: Baseline, week 10, and week 18
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.